Diagnostics & Testing

Q2 Solutions is a leading global clinical trial laboratory services organization offering end-to-end lab services, including bioanalytical testing, ADME, biospecimen management, and biobanking. It provides specialized capabilities in genomics, bioinformatics, DNA/RNA sequencing, companion diagnostics, safety testing, flow cytometry, and anatomic pathology. As an IQVIA company, it delivers tailored solutions with rapid turnaround for pharmaceutical and life sciences clinical trials.

Qlucore provides software solutions for precision medicine, including Qlucore Omics Explorer, Qlucore Insights, and Qlucore Diagnostics, enabling multi-omics data analysis, AI-powered machine learning classifiers for disease subtyping, and companion diagnostics development. Their platform supports clinical diagnostics like RNA-seq-based subtype classification for B-cell leukemias (BCP-ALL), certified under IVDR with CE-mark. It facilitates research, drug development, and scalable deployment across cancer types through visualization-based tools and plug-in models.

Quantabio provides advanced DNA and RNA amplification reagents for PCR, qPCR, RT-PCR, and NGS applications in life sciences and pharmaceutical research. Their proprietary ToughMix and qScript technologies deliver robust performance against PCR inhibitors, supporting pathogen detection, infectious disease assays, and library preparation for Illumina platforms. Products like UltraPlex 1-Step ToughMix enhance CDC protocols for respiratory disease detection, including COVID-19 and influenza.

Radiometer develops, manufactures, and markets acute care diagnostic solutions including blood gas analyzers, immunoassay analyzers, transcutaneous monitors, blood sampling syringes, and integrated IT management systems. These products support blood gas, electrolyte, metabolite, cardiac, coagulation, infection, and pregnancy marker testing in hospitals, emergency departments, and intensive care units. As part of Danaher Corporation, Radiometer provides fast, accurate diagnostics to streamline workflows and improve patient care in point-of-care and central lab settings.

Radiometer Medical ApS develops, manufactures, and markets technologically advanced solutions for acute care diagnostics, including blood gas analyzers, blood sampling, transcutaneous monitoring, immunoassay testing, and related IT management systems. These products support point-of-care testing in critical care settings, streamlining diagnostic workflows for hospitals and healthcare providers. While primarily focused on medical devices for in vitro diagnostics, their offerings aid pharmaceutical R&D in biomarker analysis and acute care evaluation.

MeMed develops host-immune response diagnostics, including the FDA-cleared MeMed BV test that distinguishes bacterial from viral infections in 15 minutes using serum or whole blood on the compact MeMed Key platform. The test measures immune proteins like TRAIL, IP-10, and CRP with machine learning for actionable scores, aiding antibiotic stewardship and reducing antimicrobial resistance. Additional products like MeMed BV Flex (FDA Breakthrough Designation for capillary blood) and MeMed Severity (for predicting severe outcomes) expand point-of-care capabilities in hospitals and decentralized settings.

Roche is a leading global healthcare company specializing in pharmaceuticals and diagnostics, with a strong focus on oncology, immunology, infectious diseases, and neuroscience. It develops innovative medicines and diagnostic tools through cutting-edge R&D, including its Pharma Research and Early Development (pRED) organization. As the world's largest biotech company by revenue, Roche partners worldwide to address unmet medical needs and deliver first-in-class therapeutics.

SMi Systems develops super-resolution single molecule imaging platforms for biomedical research and diagnostics. Their integrated system includes instruments, consumables in 96-well formats, and software for automated detection, quantification, and analysis of multiple molecule types. The patented technology enables high-throughput imaging of hundreds of thousands of molecules simultaneously, reducing project timelines and costs.

Scale Biosciences provides instrument-free, high-throughput single-cell sequencing kits for RNA, methylation, and CRISPR guide enrichment, enabling profiling of tens of thousands to millions of cells per run. Their Quantum Barcoding technology allows massively parallel sample processing with low costs, under one cent per cell, and high sensitivity. These solutions support applications like drug screening, large cohort studies, and multiomics in life sciences and pharma R&D.

SeekGene develops high-throughput single-cell technology platforms for multi-omics analysis, including simultaneous DNA methylation (5mC/5hmC), RNA transcriptomics, and immune repertoire profiling (TCR/BCR) from the same cell or nucleus. Their SeekOne™ DD solution provides a unified workflow for integrated epigenetic and transcriptomic insights at single-cell resolution. The company offers molecular biology solutions for single-cell RNA sequencing, tissue dissociation, and bioinformatic analysis.

Seer provides the Proteograph product suite, an integrated solution for unbiased deep proteomics analysis using engineered nanoparticles, automation instruments, and software. It enables biomarker discovery, target identification, and multiomics research for cancer, neurodegenerative, and metabolic diseases. Seer partners with service providers worldwide and collaborates with Thermo Fisher Scientific to promote its technology alongside Orbitrap Astral mass spectrometers.

Seer Inc. offers the Proteograph product suite, an integrated platform for deep, unbiased plasma proteomics using proprietary engineered nanoparticles, automation instruments, and analysis software. It enables large-scale proteomic profiling for biomarker discovery in areas like cancer, neurodegenerative, and metabolic diseases. The technology complements mass spectrometry systems, with a co-marketing agreement with Thermo Fisher Scientific for integration with Orbitrap Astral mass spectrometers.

Sekisui Diagnostics develops, manufactures, and supplies clinical chemistry reagents, point-of-care tests, and pre-analytic systems for laboratories, hospitals, and healthcare providers worldwide. Their portfolio includes over 65 reagents for cardiovascular, diabetes, renal, and infectious disease testing, alongside rapid antigen and molecular tests like OSOM and Metrix for COVID-19, influenza, and respiratory health. They also provide specialty enzymes and materials for biotherapeutic manufacture, pharmaceutical production, and diagnostic reagents to support R&D and scale-up processes.

Signios Bio provides an integrated suite of multiomic technologies including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology, powered by a proprietary AI-driven bioinformatics platform. The company offers next-generation sequencing services such as whole-genome sequencing, whole-exome sequencing, single-cell RNA-seq, spatial transcriptomics, and long-read PacBio sequencing. These capabilities support pharmaceutical companies, biotech firms, and academic institutions in decoding disease biology, identifying biomarkers, and advancing precision medicine and drug discovery.

Mission Bio provides single-cell multi-omics technology that simultaneously detects SNVs, CNVs, and protein data from individual cells. The Tapestri Platform enables pharmaceutical and biotech companies to conduct precision genomics analysis for oncology research, biomarker development, cell and gene therapy, and genome editing safety assessment. Their pre-designed panels target genes implicated in hematologic malignancies and solid tumors, supporting drug development and therapeutic innovation.

Quantum-Si offers benchtop proteomics platforms for single-molecule protein sequencing, enabling real-time analysis in research labs. Their Platinum and upcoming Proteus systems provide next-generation performance for biomarker discovery and therapeutic development. Key advancements include detection of up to 20 amino acids and controlled cleavage chemistry for billions of sequencing reads.

Nautilus Biotechnology pioneers single-molecule proteome analysis through its Voyager Platform, designed to measure up to 10 billion intact proteins and proteoforms simultaneously in a single run. The platform delivers accurate quantification with unprecedented dynamic range across the entire proteome, enabling pharmaceutical and research organizations to generate deep biological insights for drug discovery, biomarker identification, and disease research. Using proprietary Iterative Mapping technology and machine-learning powered analysis, the benchtop instrument requires no special lab facilities and provides reproducible, digital protein counts suitable for AI workflows.

SomaLogic provides advanced proteomics technology that measures approximately 7,000 proteins simultaneously from small biological samples, enabling biomarker discovery, diagnostics development, and drug discovery. The company's SomaScan Platform offers high specificity, sensitivity, and reproducibility, and is now part of Illumina following their acquisition. SomaLogic serves academic institutions, biopharmaceutical researchers, and clinical applications through its SomaSignal Tests for disease risk assessment and health monitoring.

SomaLogic offers the SomaScan Assay, a high-plex proteomics platform measuring over 7,000 proteins simultaneously from small plasma or serum samples with high sensitivity, specificity, and reproducibility. It supports biomarker discovery, drug development, diagnostics, and clinical testing for cardiovascular risk, cancer, and other diseases. Now part of Illumina, it enables multiomics insights for pharmaceutical R&D and health management.

Spear Bio offers SPEAR UltraDetect, a homogeneous immunoassay platform for ultrasensitive protein biomarker detection using patented two-factor authentication and qPCR amplification. It enables attomolar sensitivity from 1 µL samples, targeting neurology biomarkers like pTau231, pTau217, GFAP, and NfL for neurodegenerative disease research. The technology supports research-use-only applications with services for custom assay development and biomarker analysis.

SphingoTec GmbH develops and markets proprietary blood-based biomarkers for diagnosing, predicting, and monitoring acute conditions like acute kidney injury, sepsis, and acute heart failure. Their offerings include chemiluminescence microtiter plate assays for biomarkers such as penKid (Proenkephalin A 119-159) and bio-ADM (bioactive Adrenomedullin 1-52), designed for research and high-throughput laboratory use. They partner with companies like Beckman Coulter to enable automated assays on immunoassay analyzers for broader clinical adoption.

Standard BioTools provides precision genomic and proteomic solutions, including high-throughput instruments like Biomark X9 for PCR, genotyping, and NGS library prep, alongside CyTOF for mass cytometry and Hyperion for tissue imaging. Their multi-omic lab services support biomarker discovery, drug development, clinical trials, and pathogen detection by turning samples into high-quality data. Scalable microfluidics technology enables up to 9,216 reactions per run with reduced contamination risk and enhanced workflow efficiency.

Syndex Bio develops the proprietary mcPCR platform, which enables high-fidelity amplification of both DNA methylation patterns and genetic sequences, overcoming limitations of traditional PCR. This technology supports sensitive analysis of methylated DNA in clinical samples, particularly for non-invasive biopsies in early disease detection and cancer monitoring. Based in Cambridge, UK, the company recently raised $15.5M in seed funding to expand R&D and clinical applications.

TATAA Biocenter is a GLP-accredited CRO specializing in bioanalytical services for cell and gene therapies, including qPCR, dPCR, NGS, and proteomics. They provide biomarker discovery, assay validation, biodistribution, PK/PD analysis, and immune monitoring compliant with FDA, EMA, and GCLP standards. Their services support oligonucleotide drugs like mRNA, siRNA, ASOs, and CRISPR from preclinical to clinical stages.